- Home
- VERI vs BCAB Comparison
VERI vs BCAB Comparison
Compare VERI & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERI
- BCAB
- Stock Information
- Founded
- VERI 2014
- BCAB 2007
- Country
- VERI United States
- BCAB United States
- Employees
- VERI N/A
- BCAB N/A
- Industry
- VERI EDP Services
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- VERI Technology
- BCAB Health Care
- Exchange
- VERI Nasdaq
- BCAB Nasdaq
- Market Cap
- VERI 90.7M
- BCAB 77.8M
- IPO Year
- VERI 2017
- BCAB 2020
- Fundamental
- Price
- VERI $2.30
- BCAB $0.69
- Analyst Decision
- VERI Hold
- BCAB Buy
- Analyst Count
- VERI 1
- BCAB 2
- Target Price
- VERI $2.25
- BCAB $5.00
- AVG Volume (30 Days)
- VERI 856.6K
- BCAB 895.9K
- Earning Date
- VERI 11-12-2024
- BCAB 11-07-2024
- Dividend Yield
- VERI N/A
- BCAB N/A
- EPS Growth
- VERI N/A
- BCAB N/A
- EPS
- VERI N/A
- BCAB N/A
- Revenue
- VERI $124,881,000.00
- BCAB $11,000,000.00
- Revenue This Year
- VERI $10.27
- BCAB N/A
- Revenue Next Year
- VERI $2.47
- BCAB N/A
- P/E Ratio
- VERI N/A
- BCAB N/A
- Revenue Growth
- VERI 6.94
- BCAB N/A
- 52 Week Low
- VERI $1.48
- BCAB $0.67
- 52 Week High
- VERI $7.76
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- VERI 36.35
- BCAB 19.59
- Support Level
- VERI $2.13
- BCAB $1.17
- Resistance Level
- VERI $2.67
- BCAB $1.72
- Average True Range (ATR)
- VERI 0.21
- BCAB 0.13
- MACD
- VERI -0.01
- BCAB -0.06
- Stochastic Oscillator
- VERI 22.97
- BCAB 2.12
About VERI Veritone Inc.
Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has a presence in the United States, the United Kingdom, France, Australia, Israel and India.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.